Ramucirumab (Cyramza)
Immunotherapy · Approved since 2014
Description
Ramucirumab is a fully human monoclonal antibody that blocks blood vessel formation in tumors. In colorectal cancer, it is approved for use in combination with FOLFIRI chemotherapy as second-line treatment for metastatic disease that has progressed after first-line therapy containing bevacizumab, oxaliplatin, and a fluoropyrimidine. It is also used in combination with TAS-102 (trifluridine/tipiracil) for patients with refractory metastatic colorectal cancer.
Mechanism of Action
Ramucirumab specifically binds to the vascular endothelial growth factor receptor 2 (VEGFR-2) on endothelial cells, preventing VEGF ligands from activating this receptor. By blocking VEGFR-2 signaling, it inhibits angiogenesis and reduces tumor blood supply, ultimately limiting tumor growth and metastasis.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Cyramza |
| Category | Immunotherapy |
 Status | FDA Approved |
 EMA Status | EMA Approved |
 Spain Access | Hospital use approved in CRC |
| Administration | IV |
| Year Approved | 2014 |
| Clinical Trials | 11 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.